SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 232 filers reported holding SAGE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.89 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $451,674 | -30.9% | 9,606 | -44.0% | 0.13% | -51.7% |
| Q4 2022 | $654,025 | +17.0% | 17,148 | -0.9% | 0.26% | -5.7% |
| Q2 2022 | $559,000 | +162.4% | 17,298 | +168.8% | 0.28% | +134.5% |
| Q1 2022 | $213,000 | -27.1% | 6,435 | -2.5% | 0.12% | -35.3% |
| Q3 2021 | $292,000 | -17.7% | 6,597 | -46.6% | 0.18% | -78.1% |
| Q1 2020 | $355,000 | +7.3% | 12,359 | +583.6% | 0.84% | +282.3% |
| Q2 2019 | $331,000 | +22.1% | 1,808 | -46.8% | 0.22% | +134.0% |
| Q2 2017 | $271,000 | – | 3,400 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 312,000 | $29,886,000 | 5.11% |
| DAFNA Capital Management LLC | 104,306 | $9,991,000 | 4.97% |
| Palo Alto Investors LP | 850,977 | $81,515,000 | 4.34% |
| BB BIOTECH AG | 1,375,229 | $131,733,000 | 4.22% |
| Eventide Asset Management | 936,000 | $89,659,000 | 3.97% |
| TRV GP II, LLC | 37,362 | $3,579,000 | 3.56% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 146,179 | $14,002,000 | 2.11% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 111,908 | $10,720,000 | 2.06% |
| OAK RIDGE INVESTMENTS LLC | 231,483 | $22,174,000 | 1.60% |
| Rhenman & Partners Asset Management AB | 137,339 | $13,156,000 | 1.50% |